We Can Medicines Co., Ltd. (TPEX:6929)
Taiwan
· Delayed Price · Currency is TWD 30.85
-0.85 (-2.68%)
Mar 9, 2026, 1:05 PM CST
We Can Medicines Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 3,219 | 3,269 | 3,123 | 3,303 | 2,794 | 2,667 |
| Revenue Growth (YoY) | -1.47% | 4.69% | -5.45% | 18.20% | 4.77% | - |
| Cost of Revenue | 2,158 | 2,173 | 2,099 | 2,191 | 1,878 | 1,798 |
| Gross Profit | 1,061 | 1,097 | 1,023 | 1,112 | 916.55 | 868.45 |
| Selling, General & Admin | 1,131 | 1,147 | 1,002 | 990.45 | 886.13 | 833.87 |
| Operating Expenses | 1,132 | 1,147 | 999.52 | 994.39 | 886.22 | 833.81 |
| Operating Income | -71.1 | -50.01 | 23.94 | 117.2 | 30.33 | 34.64 |
| Interest Expense | -25.81 | -27.43 | -23.46 | -19.09 | -14.43 | -13.26 |
| Interest & Investment Income | 1.33 | 1.25 | 0.62 | 0.24 | 0.05 | 0.06 |
| Currency Exchange Gain (Loss) | -0.02 | 0.01 | -0.01 | 1.64 | -0.26 | - |
| Other Non Operating Income (Expenses) | 26.18 | 31.56 | 25.28 | 31.91 | 24.76 | 21.5 |
| EBT Excluding Unusual Items | -69.41 | -44.62 | 26.37 | 131.9 | 40.45 | 42.94 |
| Gain (Loss) on Sale of Investments | 0.24 | 0.37 | - | 0.11 | 0.19 | - |
| Gain (Loss) on Sale of Assets | -5.72 | -0.14 | -2.77 | -7.2 | -1.85 | -1.1 |
| Asset Writedown | -6.22 | -4.4 | -2 | -3.68 | - | 0.86 |
| Other Unusual Items | 2.05 | 0.5 | - | - | - | - |
| Pretax Income | -79.06 | -48.29 | 21.6 | 121.13 | 38.79 | 42.71 |
| Income Tax Expense | 0.07 | -1.12 | 6.8 | 21.08 | - | - |
| Net Income | -79.13 | -47.18 | 14.8 | 100.05 | 38.79 | 42.71 |
| Net Income to Common | -79.13 | -47.18 | 14.8 | 100.05 | 38.79 | 42.71 |
| Net Income Growth | - | - | -85.20% | 157.91% | -9.16% | - |
| Shares Outstanding (Basic) | 45 | 43 | 40 | 40 | 40 | 32 |
| Shares Outstanding (Diluted) | 45 | 43 | 42 | 42 | 40 | 32 |
| Shares Change (YoY) | 6.44% | 2.86% | 1.26% | 4.31% | 24.84% | - |
| EPS (Basic) | -1.76 | -1.09 | 0.37 | 2.50 | 0.97 | 1.33 |
| EPS (Diluted) | -1.76 | -1.09 | 0.35 | 2.40 | 0.97 | 1.33 |
| EPS Growth | - | - | -85.42% | 147.46% | -27.08% | - |
| Free Cash Flow | 259.31 | 196.73 | 47.29 | 224.13 | 117.58 | 21.05 |
| Free Cash Flow Per Share | 5.77 | 4.53 | 1.12 | 5.37 | 2.94 | 0.66 |
| Dividend Per Share | - | - | 0.270 | - | - | - |
| Gross Margin | 32.96% | 33.54% | 32.77% | 33.66% | 32.80% | 32.57% |
| Operating Margin | -2.21% | -1.53% | 0.77% | 3.55% | 1.08% | 1.30% |
| Profit Margin | -2.46% | -1.44% | 0.47% | 3.03% | 1.39% | 1.60% |
| Free Cash Flow Margin | 8.06% | 6.02% | 1.51% | 6.79% | 4.21% | 0.79% |
| EBITDA | -2.97 | 18.4 | 84.94 | 175.47 | 76.28 | 71.15 |
| EBITDA Margin | -0.09% | 0.56% | 2.72% | 5.31% | 2.73% | 2.67% |
| D&A For EBITDA | 68.13 | 68.41 | 61 | 58.27 | 45.95 | 36.51 |
| EBIT | -71.1 | -50.01 | 23.94 | 117.2 | 30.33 | 34.64 |
| EBIT Margin | -2.21% | -1.53% | 0.77% | 3.55% | 1.08% | 1.30% |
| Effective Tax Rate | - | - | 31.47% | 17.40% | - | - |
| Advertising Expenses | - | 8.16 | - | 903.85 | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.